DCE CT/MRI scanning study in patients with solid tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)
Study identifier:D1330C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Exploratory Open-Label, Non-randomised, Single Centre Methodology Study Comparing DCE-CT and DCE-MRI as Markers of Changes in Vascular Activity Mediated by a Positive Control Agent [Cediranib (Recentin™; AZD2171), a Potent Inhibitor of VEGF-driven Angiogenesis] in Patients with Advanced Solid Tumour
Medical condition
cancer
Phase
Phase 1
Healthy volunteers
No
Study drug
Recentin (Cediranib)
Sex
All
Actual Enrollment
35
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Aug 2008
Primary Completion Date: 01 Feb 2010
Study Completion Date: 01 Nov 2010
Study design
Allocation: N/A
Endpoint Classification: N/A
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other
Verification:
Verified 01 Jun 2011 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
Royal Marsden Hospital
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Open label 30mg Cediranib administered once daily during scanning phase and if tolerated by patient, until disease progression | Drug: Recentin (Cediranib) 30mg once daily, oral dose Other Name: Cediranib |
Contacts
Investigators
Principal Investigator
Jane Robertson
AstraZeneca, Alderley Park
